Zurcher Kantonalbank Zurich Cantonalbank increased its position in Xencor, Inc. (NASDAQ:XNCR – Get Rating) by 29.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 8,072 shares of the biopharmaceutical company’s stock after acquiring an additional 1,816 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Xencor were worth $324,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in XNCR. KBC Group NV bought a new position in shares of Xencor in the third quarter valued at approximately $97,000. PNC Financial Services Group Inc. boosted its position in shares of Xencor by 54.4% in the third quarter. PNC Financial Services Group Inc. now owns 3,953 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 1,393 shares during the period. Royal Bank of Canada boosted its position in shares of Xencor by 145.4% in the second quarter. Royal Bank of Canada now owns 5,417 shares of the biopharmaceutical company’s stock valued at $187,000 after acquiring an additional 3,210 shares during the period. Gotham Asset Management LLC bought a new stake in Xencor during the third quarter valued at approximately $224,000. Finally, Teacher Retirement System of Texas lifted its position in Xencor by 23.0% during the third quarter. Teacher Retirement System of Texas now owns 8,352 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 1,562 shares during the last quarter. Institutional investors own 98.78% of the company’s stock.
Shares of NASDAQ XNCR opened at $26.34 on Friday. Xencor, Inc. has a 52 week low of $25.45 and a 52 week high of $44.80. The firm’s fifty day moving average is $28.79 and its 200 day moving average is $34.25. The company has a market cap of $1.54 billion, a price-to-earnings ratio of 19.51 and a beta of 0.81.
XNCR has been the subject of several research analyst reports. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Thursday, February 17th. Sumitomo Mitsui Financial Group initiated coverage on shares of Xencor in a research report on Friday, January 21st. They set an “outperform” rating and a $60.00 target price for the company. BMO Capital Markets initiated coverage on shares of Xencor in a research report on Friday, February 11th. They set an “outperform” rating and a $54.00 target price for the company. HC Wainwright dropped their target price on shares of Xencor from $61.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, February 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Xencor in a research note on Friday, April 1st. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $53.88.
In other Xencor news, CMO Allen Yang sold 1,200 shares of the business’s stock in a transaction on Wednesday, March 9th. The shares were sold at an average price of $28.94, for a total transaction of $34,728.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO John J. Kuch sold 971 shares of the business’s stock in a transaction on Thursday, March 3rd. The shares were sold at an average price of $29.86, for a total transaction of $28,994.06. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,524 shares of company stock worth $279,886. 3.68% of the stock is owned by insiders.
Xencor Profile (Get Rating)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Xencor (XNCR)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.